The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy of Tenofovir Disoproxil Fumarate in Antiretroviral Therapy–Naive and –Experienced Patients Coinfected with HIV‐1 and Hepatitis B Virus
Abstract
BACKGROUND: Coinfection with human immunodeficiency virus type 1 (HIV-1) increases the risk of hepatitis B virus (HBV)-associated progressive liver disease. Lamivudine has potent activity against both HIV-1 and HBV; however, lamivudine-resistance mutations in HBV frequently develop. METHODS: Substudies of the safety and efficacy of tenofovir disoproxil fumarate (tenofovir DF) for patients coinfected with HIV and HBV were undertaken within 2 phase 3 randomized controlled trials involving antiretroviral therapy-experienced (study 907) and -naive (study 903) HIV-infected populations. Inclusion criteria were detection of hepatitis B surface antigen, an HBV DNA level >106 copies/mL at baseline, and HBV DNA specimens available at week 24 (study 907) and week 48 (study 903). RESULTS: In study 907, the mean decrease in HBV DNA was 4.9 log(10), after 24 weeks, for 10 patients randomized to receive tenofovir DF, compared with a mean increase of 1.2 log(10) for 2 patients randomized to receive placebo (P=.041). The mean decrease in HBV DNA during tenofovir DF treatment was similar for patients with wild-type (5.3 log(10)) and lamivudine-resistant (4.6 log(10)) HBV strains. In study 903, the mean decrease in HBV DNA was 3.0 log(10), after 48 weeks, for 6 patients randomized to receive lamivudine, compared with 4.7 log(10) for 5 patients randomized to receive lamivudine and tenofovir DF (P=.055). Four patients developed tyrosine-methionine-aspartate-aspartate mutations, all in the lamivudine-only treatment arm. CONCLUSION: Tenofovir DF has potent anti-HBV efficacy in antiretroviral therapy-experienced and -naive individuals coinfected with HIV and HBV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
Marcellin, P., Chang, T.-T., Lim, S. G., Tong, M. J., Sievert, W., Shiffman, M. L., Jeffers, L., Goodman, Z., Wulfsohn, M. S., Xiong, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020681 · Cited by 1,336
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Thio, C. L., Seaberg, E. C., Skolasky, R., Phair, J., Visscher, B., Muñoz, A., & Thomas, D. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11913-1 · Cited by 1,099
Hammer, S. M., Katzenstein, D. A., Hughes, M. D., Gundacker, H., Schooley, R. T., Haubrich, R. H., Henry, W. K., Lederman, M. M., Phair, J. P., Niu, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610103351501 · Cited by 1,091
Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
Hadziyannis, S. J., Tassopoulos, N. C., Heathcote, E. J., Chang, T.-T., Kitis, G., Rizzetto, M., Marcellin, P., Lim, S. G., Goodman, Z., Wulfsohn, M. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021812 · Cited by 995
Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R., & Snydman, D. R. (2001) · Clinical Infectious Diseases · doi:10.1086/318501 · Cited by 974
Sulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30319 · Cited by 523
Darbyshire, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05387-1 · Cited by 509
Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510300525 · Cited by 424
den Brinker, M., Wit, F. W. N. M., Wertheim-van Dillen, P. M. E., Jurriaans, S., Weel, J., van Leeuwen, R., Pakker, N. G., Reiss, P., Danner, S. A., Jan Weverling, G., et al. (2000) · AIDS · doi:10.1097/00002030-200012220-00011 · Cited by 390
Long-term therapy of chronic hepatitis B with lamivudine
Lau, D. T.-Y., Khokhar, F. M., Doo, E., Ghany, M. G., Herion, D., Park, Y., Kleiner, D. E., Schmid, P., Condreay, L. D., Gauthier, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17912 · Cited by 348
Mommeja-Marin, H., Mondou, E., Blum, R. M., & Rousseau, F. (2003) · Hepatology · doi:10.1053/jhep.2003.50208 · Cited by 275
Bodsworth, N. J., Cooper, D. A., & Donovan, B. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.5.1138 · Cited by 267
Self-citationDe Luca, A. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2125 · Cited by 229
Kahn, J. (1999) · JAMA · doi:10.1001/jama.282.24.2305 · Cited by 199
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial
Squires, K., Pozniak, A. L., Pierone, G., Steinhart, C. R., Berger, D., Bellos, N. C., Becker, S. L., Wulfsohn, M., Miller, M. D., Toole, J. J., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00006 · Cited by 198
Self-citationTorresi, J. (2002) · Journal of Clinical Virology · doi:10.1016/s1386-6532(02)00049-5 · Cited by 193
Carr, A., & Cooper, D. A. (1997) · The Lancet · doi:10.1016/s0140-6736(05)62892-9 · Cited by 169
Self-citationAceti, A., Pasquazzi, C., Zechini, B., et al. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200201010-00005 · Cited by 145
Savès, M., Raffi, F., Clevenbergh, P. A., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.12.3451-3455.2000 · Cited by 115
Gisolf, E. H., Dreezen, C., Danner, S. A., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/317449 · Cited by 96
Hoff, J., Bani‐Sadr, F., Gassin, M., & Raffi, F. (2001) · Clinical Infectious Diseases · doi:10.1086/319368 · Cited by 88
Sinicco, A., Raiteri, R., Sciandra, M., Bertone, C., Lingua, A., Salassa, B., & Gioannini, P. (1997) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365549709035869 · Cited by 78
Treatment of chronic hepatitis B: Case selection and duration of therapy
Leung, N. W. Y. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02767.x · Cited by 72
A Cohort Study of Nevirapine Tolerance in Clinical Practice: French Aquitaine Cohort, 1997–1999
Bonnet, F., Lawson‐Ayayi, S., Thiébaut, R., Ramanampamonjy, R. M., Lacoste, D., Bernard, N., Malvy, D. J.-M., Bonarek, M., Djossou, F., Beylot, J., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/343046 · Cited by 49
HEPATOTOXICITY FOLLOWING NEVIRAPINE-CONTAINING REGIMENS IN HIV-1-INFECTED INDIVIDUALS
de Maat, M. M. R., Mathôt, R. A. A., Veldkamp, A. I., Huitema, A. D. R., Mulder, J. W., Meenhorst, P. L., Gorp, E. C. M. V., Carlier, H., & Beijnen, J. H. (2002) · Pharmacological Research · doi:10.1016/s1043-6618(02)00146-9 · Cited by 45
Cited by
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Lok, A. S. F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,087
Chronic hepatitis B: Update 2009 #
Lok, A. S. F., & McMahon, B. J. (2009) · Hepatology · doi:10.1002/hep.23190 · Cited by 2,831
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,089
Metadata
- Authors
- Dore, G. J., Cooper, D. A., Pozniak, A. L., DeJesus, E., Zhong, L., Miller, M. D., Lu, B., Cheng, A. K., & Teams, T. 9. A. 9. S.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-04
- Volume
- 189
- Issue
- 7
- Pages
- 1185-1192
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2029914836
- Cited by
- 253
- References
- 27
- FWCI
- 23.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.